A research team at the Francis Crick Institute and Great Ormond Street Hospital (GOSH)/UCL Great Ormond Street Institute of Child Health have identified new potential treatments for children with rare genetic conditions of blood vessels, which cause severe, lifelong, and disabling symptoms like seizures and impaired development.
Gilead wins FDA accelerated approval of seladelpar after acquiring it in $4.3B deal
Six months after buying CymaBay Therapeutics for $4.3 billion, Gilead has secured accelerated approval for seladelpar, the primary biliary cholangitis drug that was at the
August 15, 2024